MabCampath recall in Canada: Risk of serious immune reactions and stroke
In plain language
This recall involves MabCampath (alemtuzumab) 30 mg/mL, 1mL vials sold in Canada. It's being recalled because new safety information shows a risk of serious immune reactions, stroke, and kidney inflammation. Patients should speak with their healthcare professional if they experience new or worsening symptoms.
What to do
- Immediately speak with your healthcare professional if you are taking MabCampath and experience new or worsening symptoms.
- Symptoms include persistent fever, swollen lymph glands, enlarged spleen or liver, bruising, skin rash, or abnormal blood values.
- Also watch for drooping of parts of the face, weakness on one side of the body, difficulty talking, sudden severe headache, swelling in the face, hands, feet, abdomen, high blood pressure, or pink, cola-colored or foamy urine.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
MabCampath (alemtuzumab) 30 mg/mL, 1mL vial
Why this matters
Risk of Haemophagocytic Lymphohistiocytosis, Stroke, and Glomerulonephritis
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of Haemophagocytic Lymphohistiocytosis, Stroke, and Glomerulonephritis
What should consumers do?
Immediately speak with your healthcare professional if you are taking MabCampath and experience new or worsening symptoms. Symptoms include persistent fever, swollen lymph glands, enlarged spleen or liver, bruising, skin rash, or abnormal blood values. Also watch for drooping of parts of the face, weakness on one side of the body, difficulty talking, sudden severe headache, swelling in the face, hands, feet, abdomen, high blood pressure, or pink, cola-colored or foamy urine.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of Haemophagocytic Lymphohistiocytosis, Stroke, and Glomerulonephritis
When was this product recalled?
This product was recalled on June 22, 2020.
Is the MabCampath brand affected by this recall?
Yes, MabCampath products are affected by this recall. This recall involves MabCampath (alemtuzumab) 30 mg/mL, 1mL vials sold in Canada. It's being recalled because new safety information shows a risk of serious immune reactions, stroke, and kidney inflammation. Patients should speak with their healthcare professional if they experience new or worsening symptoms.